ALX Oncology Holdings, Inc. (ALXO)

Over the past six months, ALX Oncology completed a registered offering, strengthening its balance sheet with net proceeds of $140.4 million. The company reported its first-quarter 2026 financial results, missing analysts' EPS expectations by $0.02, but the stock traded up by 11.2% during midday trading on May 8, 2026. Encouraging Phase 1b/2 data for evorpacept in combination with zanidatamab in heavily pretreated HER2-positive breast cancer patients was presented at ESMO Breast Cancer 2026. CEO Jason Lettmann sold 12,311 shares of the company's stock for $26,714.87. Analyst ratings have varied, including a downgrade, reaffirmed buy and sell ratings, and new coverage initiated. The stock's 52-week range has been between $0.40 and $2.66, closing at $2.08 as of May 8, 2026.

As a clinical-stage biopharmaceutical company without commercialized products, ALX Oncology Holdings Inc. does not experience demand seasonality in the traditional sense. The company's operations and financial performance are primarily driven by research and development progress, clinical trial execution, regulatory milestones, and access to funding.

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies by blocking the CD47 immune checkpoint inhibitor. Their lead product candidate, evorpacept, aims to enhance the immune system's ability to recognize and eliminate cancer cells and is being evaluated in various clinical trials. The company also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC, and ALX2004, a differentiated EGFR-targeted ADC, which is in Phase 1 dose escalation.

ALX Oncology Holdings Inc. is headquartered in South San Francisco, California, and focuses on developing therapies for cancer patients in the United States.

ALX Oncology's brand reputation has been positively influenced by encouraging clinical data, regular corporate updates, and continued analyst coverage. The presentation of durable responses observed with evorpacept in combination with zanidatamab in HER2-positive breast cancer patients reinforces the potential of their lead candidate. Regular reporting of financial results and corporate updates contributes to a perception of stability and progress. Continued coverage and ratings from equities research analysts indicate ongoing interest and scrutiny within the investment community.

ALX Oncology Holdings Inc. has significant institutional ownership, with 62 institutional owners and shareholders holding a total of 29,232,383 shares, accounting for approximately 42.5% of the company. Individuals hold about 1.29%. Major institutional shareholders include venBio Partners LLC, Redmile Group, LLC, and Millennium Management Llc, among others.